Información del artículo
El Texto completo está disponible en PDF
References
[1]
G.R.V. Hughes.
Thrombosis, abortion, cerebral disease, and the lupus anticoagulant.
BMJ, 287 (1983), pp. 1088-1089
[2]
G. Ruiz-Irastorza, M. Crowther, M.A. Khamashta.
Antiphosphlipid syndrome.
The Lancet, 376 (2010), pp. 1498-1509
[3]
G.R.V. Hughes.
The antiphospholipid syndrome: ten years on.
The Lancet, 342 (1993), pp. 341-344
[4]
W.A. Wilson, A.E. Gharavi, T. Koike, et al.
International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome.
Arthritis Rheum, 42 (1999), pp. 1309-1311
[5]
S. Miyakis, M.D. Lockshin, T. Atsumi, et al.
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).
J Thromb Haemost, 4 (2006), pp. 295-306
[6]
R. Cervera, J.C. Plette, J. Font, et al.
Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients.
Arthritis Rheum, 46 (2002), pp. 1019-1027
[7]
R. Cervera, R.A. Asherson.
Sindrome antifosfolipidico: nuevas perspectivas clinicas y terapeuticas.
Reumatol Clin, 1 (2005), pp. 183-186
[8]
Giannakopoulos, F. Passam, Y. Ioannou, S.A. Krilis.
How we diagnose the antiphospholipid syndrome.
Blood, 113 (2009), pp. 985-994
[9]
G.R.V. Hughes, M.A. Khamashta.
Seronegative antiphospholipid syndrome.
Ann Rheum Dis, 62 (2003), pp. 1127
[10]
A. Joseph, R. Brasington, L. Kahl, P. Ranganathan, T.P. Cheng, J. Atkinson.
Immunologic rheumatic disorders.
J Allergy Clin Immunol, 125 (2010), pp. S204-S215
[11]
B. Giannakopoulos, S.A. Krilis.
How I treat the antiphospholipid syndrome.
Blood, 114 (2009), pp. 2020-2030
[12]
J.I. Tuthill, M.A. Khamashta.
Management of antiphospholipid syndrome.
J Autoimm, 33 (2009), pp. 92-98
[13]
N. Fernandez-Llanio, C. Alegre-Sancho, C. Chalmeta-Verdejo, et al.
Terapias hormonales, fertilidad y embarazo en el syndrome antifosfolipidico.
Reumatol Clin, 2 (2006), pp. 90-106
[14]
Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody positive patients: Report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus. 2011; 20:206-18.
[15]
E. Ortona, A. Capozzi, T. Colasanti, et al.
Vimentin/cardiolipin complex as a new antigenic target of the antiphospholipid syndrome.
Blood, 116 (2010), pp. 2960-2967
[16]
B. De Laat, R.H. Derkson, R.T. Urbanus, P.G. De Groot.
IgG antibodies that recognise epitope Gly40- Arg43 in domain 1 of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis.
Blood, 105 (2005), pp. 1540-1545
[17]
H. Cohen, S. Machin.
Antithrombotic treatment failures in antiphospholipid syndrome: the new anticoagulants?.
Lupus, 19 (2010), pp. 486-491
Copyright © 2011. Elsevier España, S.L.. All rights reserved
